Therapy News and Research

RSS

UT Southwestern surgeons to perform first hand transplant in North Texas

A team of surgeons at UT Southwestern Medical Center expects to perform the first hand transplant in North Texas within a year, making the institution just the sixth hospital in the U.S. to perform the rare and intricate surgery.

30 Aug 2011

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer.

30 Aug 2011

Ecstasy redesigned for use against blood cancer

The illicit drug ecstasy has been redesigned by researchers at the University of WA for use in treatment of blood cancers.

30 Aug 2011

Governor Perry attacked for choosing new medical treatment

Recently, the governor of Texas and presidential hopeful had a bad back treated by injecting some of his very own fat cells, after they had been cultured and treated in a laboratory. The innovative use of a patient’s own adult stem cells is showing great promise in many conditions, including damaged joints.

29 Aug 2011

Student researchers throughout Australia compete for annual award

Student researchers from throughout Australia will compete for state and national titles in the country’s leading competition for life science, biotechnology and bio-engineering students: the 2011 AusBiotech-GSK Student Excellence Awards. Applications are now open for the 2011 awards.

29 Aug 2011

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Pfizer Inc. has received FDA approval of XALKORI (crizotinib) capsules - the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

29 Aug 2011

Bioness announces commercial release of NESS L300 Plus System

Bioness Inc., today announced the commercial release of its NESS L300 Plus System. Cleared by the U.S. Food and Drug Administration (FDA) earlier this year, the L300 Plus combines the award winning NESS L300 Foot Drop System with a thigh cuff to activate even more of the nerves and muscles in the leg for greater control while walking.

29 Aug 2011

BIOTRONIK's Selectra left ventricular lead delivery system receives European market approval

BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.

29 Aug 2011

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

A specific inhibitor of the small regulatory RNA-molecule "microRNA-100" can be used to stimulate the growth of new blood vessels, if a major artery is chronically occluded.

29 Aug 2011

European infusion therapy device market to reach €533 million by 2017: New report

According to a new report by iData Research, the leading global authority in medical device market research, the European infusion therapy device market, which includes needleless connectors, infusion pumps and intravenous (IV) sets, was valued at an estimated €443 million in 2010.

29 Aug 2011

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

New data from two RE-LY trial sub-group analyses show that dabigatran etexilate provides consistent benefits in stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil.

29 Aug 2011

Nature Medicine publishes research on leukemia stem cells

Cancer scientists have long debated whether all cells within a tumour are equal or whether some cancer cells are more potent - a question that has been highly investigated in experimental models in the last decade.

29 Aug 2011

EAS/ESC develops new dyslipidaemias guidelines

Clinicians should aim for comprehensive lipid control using lifestyle as a first step and tailoring treatment to patients. Lifestyle interventions, including stopping smoking, improving diet, exercising sufficiently and moderate alcohol consumption, should be the crucial first step for managing lipids in all patients.

29 Aug 2011

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) – medicines known to significantly lower stroke risk in these patients.

29 Aug 2011

Medical engineers develop sensor chip to monitor cancerous tumors

A surgery is usually one of the first therapy options in cancer treatment. However, some tumors, such as brain tumors, can be difficult to operate on if there is a risk of damaging surrounding nerve tissue.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

MitraClip treatment could benefit heart failure patients who are unresponsive to CRT

Results of an observational study presented at the European Society of Cardiology (ESC) meeting today in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular (LV) remodeling in patients with mitral regurgitation (MR), who do not respond to cardiac resynchronization therapy.

29 Aug 2011

Colchicine more effective than placebo for recurrent pericarditis

Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011

Therapy News and Research

UT Southwestern surgeons to perform first hand transplant in North Texas

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

Ecstasy redesigned for use against blood cancer

Governor Perry attacked for choosing new medical treatment

Student researchers throughout Australia compete for annual award

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Bioness announces commercial release of NESS L300 Plus System

BIOTRONIK's Selectra left ventricular lead delivery system receives European market approval

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

European infusion therapy device market to reach €533 million by 2017: New report

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

Nature Medicine publishes research on leukemia stem cells

EAS/ESC develops new dyslipidaemias guidelines

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

Medical engineers develop sensor chip to monitor cancerous tumors

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

MitraClip treatment could benefit heart failure patients who are unresponsive to CRT

Colchicine more effective than placebo for recurrent pericarditis

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News